485 related articles for article (PubMed ID: 27717710)
21. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
[TBL] [Abstract][Full Text] [Related]
22. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
[TBL] [Abstract][Full Text] [Related]
23. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype.
Simpson NE; Tryndyak VP; Pogribna M; Beland FA; Pogribny IP
Epigenetics; 2012 Dec; 7(12):1413-20. PubMed ID: 23117580
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
25. Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Zhao Y; Jiang B; Gu Z; Chen T; Yu W; Liu S; Liu X; Chen D; Li F; Chen W
Eur J Med Chem; 2023 Jan; 246():115028. PubMed ID: 36528996
[TBL] [Abstract][Full Text] [Related]
26. Cancer drug discovery targeting histone methyltransferases: an update.
Zhao H; Wang Y; Li H
Curr Med Chem; 2015; 22(17):2075-86. PubMed ID: 25850768
[TBL] [Abstract][Full Text] [Related]
27. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
[TBL] [Abstract][Full Text] [Related]
28. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
Jin W; Chen L; Chen Y; Xu SG; Di GH; Yin WJ; Wu J; Shao ZM
Breast Cancer Res Treat; 2010 Sep; 123(2):359-73. PubMed ID: 19943104
[TBL] [Abstract][Full Text] [Related]
29. Targeting protein methylation: from chemical tools to precision medicines.
Dilworth D; Barsyte-Lovejoy D
Cell Mol Life Sci; 2019 Aug; 76(15):2967-2985. PubMed ID: 31104094
[TBL] [Abstract][Full Text] [Related]
30. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
32. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
34. A coupled fluorescent assay for histone methyltransferases.
Collazo E; Couture JF; Bulfer S; Trievel RC
Anal Biochem; 2005 Jul; 342(1):86-92. PubMed ID: 15958184
[TBL] [Abstract][Full Text] [Related]
35. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive.
Guccione E; Bassi C; Casadio F; Martinato F; Cesaroni M; Schuchlautz H; Lüscher B; Amati B
Nature; 2007 Oct; 449(7164):933-7. PubMed ID: 17898714
[TBL] [Abstract][Full Text] [Related]
36. Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.
Wang MY; Liow P; Guzman MIT; Qi J
ACS Chem Biol; 2022 Apr; 17(4):744-755. PubMed ID: 35363464
[TBL] [Abstract][Full Text] [Related]
37. KMT2C and KMT2D aberrations in breast cancer.
Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
Trends Cancer; 2024 Jun; 10(6):519-530. PubMed ID: 38453563
[TBL] [Abstract][Full Text] [Related]
38. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
39. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
40. Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer.
Salz T; Deng C; Pampo C; Siemann D; Qiu Y; Brown K; Huang S
Mol Cancer Res; 2015 Mar; 13(3):461-9. PubMed ID: 25373480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
